Open an account

Design Therapeutics

DSGN · NASDAQ

$11.10+$0.46 (+4.32%)TodayMarket closed ·
Prev close $10.64

About DSGN

Design Therapeutics, Inc. operates as a biotechnology company that develops therapies for serious degenerative disorders. The company is headquartered in Carlsbad, California and currently employs 54 full-time employees. The company went IPO on 2021-03-26. The company is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. The company is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its Huntington's Disease program is focused on the development of a potentially disease-modifying treatment for HD.

Employees
54
Headquarters
Carlsbad, California
Listed
Mar 26, 2021
Sector
Health Care
Industry
Biotechnology
Website
designtx.com

DSGN key statistics

Market cap
694.66M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
564.92K
Volume
580.81K
Open price
$10.65
High today
$11.50
Low today
$10.65
52 Week high
$17.25
52 Week low
$5.28

Design Therapeutics (DSGN) at a glance

As of Oct 20, 2026, Design Therapeutics (DSGN) shares are priced at $11.10, giving the company a market cap of 694.66M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $10.65 and $11.50. The current price is 4.2% above the day's low and 3.5% below its high.

Volume so far is 580.81K shares, in line with the average of 564.92K shares a day.

Over the past year Design Therapeutics has ranged from $5.28 to $17.25, and now sits 49% of the way up that range.

Design Therapeutics met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.32 per share against an estimate of -$0.3512.

The average analyst price target is $21.42, 93.0% above the current price, from 6 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 6 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 8 analystsAvg $21.42
Low
$20.20
Now
$11.10
High
$23.10

DSGN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 13.5% on average.

  1. Q3 FY24: reported -$0.23 per share against an estimate of -$0.2482
  2. Q4 FY24: reported -$0.24 per share against an estimate of -$0.272
  3. Q1 FY25: reported -$0.31 per share against an estimate of -$0.2856
  4. Q2 FY25: reported -$0.34 per share against an estimate of -$0.3366
  5. Q3 FY25: reported -$0.30 per share against an estimate of -$0.3502
  6. Q4 FY25: reported -$0.27 per share against an estimate of -$0.3611
  7. Q1 FY26: reported -$0.29 per share against an estimate of -$0.3349
  8. Q2 FY26: reported -$0.32 per share against an estimate of -$0.3512

DSGN news

  • Avi Kapoor

    Crude Oil Gains Over 2%; US Homebuilder Sentiment Increases In May

  • Avi Kapoor

    Nasdaq Down 200 Points; Brady Earnings Top Views

  • Avi Kapoor

    Jim Cramer: Design Therapeutics Is 'Pure Spec,' Buy This Health Care Stock

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • Avi Kapoor

    Sangamo Therapeutics, Dave And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

  • Avi Kapoor

    Lamb Weston Posts Weak Q2 Results, Joins Micron, Lennar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

  • Avi Kapoor

    Why Sangamo Therapeutics Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket

Similar companies

Companies in the same industry as Design Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.